The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies in individuals with these pathogenic or likely pathogenic variants. This manuscript focuses on cancer risk and risk management for BRCA-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies. There is also evidence that risks of prostate cancer and pancreatic cancer are elevated in these carriers. Li-Fraumeni syndrome is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Self-citationAmerican Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H., Tilanus-Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,687
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Self-citationCancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?
LI, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,509
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Self-citationProphylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Self-citationEfficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,423
Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji372 · Cited by 1,339
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,251
Self-citationAlsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171
Self-citationKuhl, C. K., Schrading, S., Leutner, C. C., Morakkabati-Spitz, N., Wardelmann, E., Fimmers, R., Kuhn, W., & Schild, H. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.4960 · Cited by 1,147
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048
Mandelson, M. T. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.13.1081 · Cited by 1,031
Skaane, P., Bandos, A. I., Gullien, R., Eben, E. B., Ekseth, U., Haakenaasen, U., Izadi, M., Jebsen, I. N., Jahr, G., Krager, M., et al. (2013) · Radiology · doi:10.1148/radiol.12121373 · Cited by 1,012
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Self-citationMedeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 916
Castro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 850
Ciatto, S., Houssami, N., Bernardi, D., Caumo, F., Pellegrini, M., Brunelli, S., Tuttobene, P., Bricolo, P., Fantò, C., Valentini, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70134-7 · Cited by 838
Pathogenic Germline Variants in 10,389 Adult Cancers
Huang, K.-L., Mashl, R. J., Wu, Y., Ritter, D. I., Wang, J., Oh, C., Paczkowska, M., Reynolds, S., Wyczalkowski, M. A., Oak, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.039 · Cited by 833
Self-citationMenon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70026-9 · Cited by 829
Lakhani, S. R., van de Vijver, M. J., Jacquemier, J., Anderson, T. J., Osin, P. P., McGuffog, L., & Easton, D. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 823
Cummings, S. R. (1999) · Medical Entomology and Zoology · Cited by 797
Inherited Mutations in Women With Ovarian Carcinoma
Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Yi, Q., Burger, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5495 · Cited by 769
Self-citationRevisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Holmfeldt, L., Wei, L., Diaz-Flores, E., Walsh, M., Zhang, J., Ding, L., Payne-Turner, D., Churchman, M., Andersson, A., Chen, S.-C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2532 · Cited by 731
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 691
Self-citationMartino, S., Cauley, J. A., Barrett-Connor, E., Powles, T. J., Mershon, J., Disch, D., Secrest, R. J., Cummings, S. R., & For the CORE Investigators (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh319 · Cited by 684
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 672
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Isaacs, C., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 672
Self-citationImpact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation
Finch, A. P. M., Lubinski, J., Møller, P., Singer, C. F., Karlan, B., Senter, L., Rosen, B., Maehle, L., Ghadirian, P., Cybulski, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2820 · Cited by 664
Self-citationVogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0076 · Cited by 646
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642
Self-citationContralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 621
Oral Contraceptives and the Risk of Hereditary Ovarian Cancer
Narod, S. A., Risch, H., Moslehi, R., Dørum, A., Neuhausen, S., Olsson, H., Provencher, D., Radice, P., Evans, G., Bishop, S., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390702 · Cited by 615
Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., Bishop, T., Benitez, J., Rivas, C., Bignon, Y.-J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2424 · Cited by 611
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 609
Self-citationAtchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6231 · Cited by 604
Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A. K., & Zhang, W. (2011) · JAMA · doi:10.1001/jama.2011.1456 · Cited by 599
Self-citationCuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R. E., von Minckwitz, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62292-8 · Cited by 590
Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C., Evans, D. G., Lynch, H., Eeles, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9626 · Cited by 589
Self-citationHu, C., Hart, S. N., Polley, E. C., Gnanaolivu, R., Shimelis, H., Lee, K. Y., Lilyquist, J., Na, J., Moore, R., Antwi, S. O., et al. (2018) · JAMA · doi:10.1001/jama.2018.6228 · Cited by 577
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
Self-citationMultiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 557
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A.-R., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 556
Villani, A., Shore, A., Wasserman, J. D., Stephens, D., Kim, R. H., Druker, H., Gallinger, B., Naumer, A., Kohlmann, W., Novokmet, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30249-2 · Cited by 546
Self-citationNarod, S. A., Brunet, J.-S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 543
Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00029 · Cited by 541
Self-citationCancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
Kratz, C. P., Achatz, M. I., Brugières, L., Frebourg, T., Garber, J. E., Greer, M.-L. C., Hansford, J. R., Janeway, K. A., Kohlmann, W. K., McGee, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0408 · Cited by 534
Self-citationMandelker, D., Zhang, L., Kemel, Y., Stadler, Z. K., Joseph, V., Zehir, A., Pradhan, N., Arnold, A., Walsh, M. F., Li, Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.11137 · Cited by 511
Self-citationMalkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Cuzick, J., Sestak, I., Bonanni, B., Costantino, J. P., Cummings, S., DeCensi, A., Dowsett, M., Forbes, J. F., Ford, L., LaCroix, A. Z., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60140-3 · Cited by 495
Mai, P. L., Best, A. F., Peters, J. A., DeCastro, R. M., Khincha, P. P., Loud, J. T., Bremer, R. C., Rosenberg, P. S., & Savage, S. A. (2016) · Cancer · doi:10.1002/cncr.30248 · Cited by 486
Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., & Muto, M. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2622 · Cited by 485
Rafferty, E. A., Park, J. M., Philpotts, L. E., Poplack, S. P., Sumkin, J. H., Halpern, E. F., & Niklason, L. T. (2012) · Radiology · doi:10.1148/radiol.12120674 · Cited by 481
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Copson, E. R., Maishman, T. C., Tapper, W. J., Cutress, R. I., Greville-Heygate, S., Altman, D. G., Eccles, B., Gerty, S., Durcan, L. T., Jones, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30891-4 · Cited by 481
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
Birch, Hartley, Tricker, Prosser, P., Condie, Kelsey, Harris, Jones, Binchy, Crowther, et al. (1994) · Cancer Research · Cited by 475
Tan, D. S. P., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-Jones, A., Norman, A., Kaye, S. B., & Gore, M. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1703 · Cited by 469
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
Shindo, K., Yu, J., Suenaga, M., Fesharakizadeh, S., Cho, C., Macgregor-Das, A., Siddiqui, A., Witmer, P. D., Tamura, K., Song, T. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.3502 · Cited by 458
Self-citationEisen, A., Lubinski, J., Klijn, J., Moller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 443
Self-citationMurphy, K. M., Brune, K. A., Griffin, C. A., Sollenberger, J. E., Petersen, G. M., Bansal, R. K., Hruban, R. H., & Kern, S. E. (2002) · PubMed · Cited by 435
Improved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
Self-citationBreast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers
Tai, Y. C., Domchek, S., Parmigiani, G., & Chen, S. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm203 · Cited by 430
Self-citationPowles, T. J., Ashley, S., Tidy, A., Smith, I. E., & Dowsett, M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk050 · Cited by 430
Zhang, S., Royer, R., Li, S., McLaughlin, J. R., Rosen, B., Risch, H. A., Fan, I., Bradley, L., Shaw, P. A., & Narod, S. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.020 · Cited by 423
Villani, A., Tabori, U., Schiffman, J., Shlien, A., Beyene, J., Druker, H., Novokmet, A., Finlay, J., & Malkin, D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70119-x · Cited by 423
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
Birch, J. M., Hartley, A. L., Tricker, K. J., Prosser, J., Condie, A., Kelsey, A. M., Harris, M., Jones, P. H. M., Binchy, A., & Crowther, D. (1994) · PubMed · Cited by 421
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
Liede, A., Karlan, B. Y., & Narod, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.055 · Cited by 407
Self-citationBuys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., Sharma, L., Saam, J., Lancaster, J., & Daly, M. B. (2017) · Cancer · doi:10.1002/cncr.30498 · Cited by 399
Self-citationGermline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7401 · Cited by 398
Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Narod, S. A. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.23.1773 · Cited by 380
Finch, A., Shaw, P., Rosen, B., Murphy, J., Narod, S. A., & Colgan, T. J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.06.065 · Cited by 375
Powell, C. B., Kenley, E., Chen, L.-M., Crawford, B., McLennan, J., Zaloudek, C., Komaromy, M., Beattie, M., & Ziegler, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.109 · Cited by 372
Nicolosi, P., Ledet, E., Yang, S., Michalski, S., Freschi, B., O’Leary, E., Esplin, E. D., Nussbaum, R. L., & Sartor, O. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6760 · Cited by 365
BRCA2 germline mutations in male breast cancer cases and breast cancer families
Couch, F. J., Farid, L. M., DeShano, M. L., Tavtigian, S. V., Calzone, K., Campeau, L., Peng, Y., Bogden, B., Chen, Q., Neuhausen, S., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-123 · Cited by 363
Self-citationLi-Fraumeni syndrome – a molecular and clinical review
Varley, J., Evans, D., & Birch, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.328 · Cited by 358
Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M., Zlotogora, J., Heching, N. I., & Peretz, T. (1997) · Europe PMC (PubMed Central) · Cited by 357
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 354
2009 Version of the Chompret Criteria for Li Fraumeni Syndrome
Tinat, J., Bougeard, G., Baert-Desurmont, S., Vasseur, S., Martin, C., Bouvignies, E., Caron, O., Bressac-de Paillerets, B., Berthet, P., Dugast, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7967 · Cited by 348
Na, R., Zheng, S. L., Han, M., Yu, H., Jiang, D., Shah, S., Ewing, C. M., Zhang, L., Novakovic, K., Petkewicz, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.11.033 · Cited by 343
Sensitivity and predictive value of criteria for p53 germline mutation screening
CHOMPRET, A., ABEL, A., STOPPA-LYONNET, D., BRUGIÈRES, L., PAGÈS, S., FEUNTEUN, J., & BONAÏTI-PELLIÉ, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.1.43 · Cited by 341
Sardanelli, F., Podo, F., D'Agnolo, G., Verdecchia, A., Santaquilani, M., Musumeci, R., Trecate, G., Manoukian, S., Morassut, S., de Giacomi, C., et al. (2007) · Radiology · doi:10.1148/radiol.2423051965 · Cited by 339
Skaane, P., Bandos, A. I., Eben, E. B., Jebsen, I. N., Krager, M., Haakenaasen, U., Ekseth, U., Izadi, M., Hofvind, S., & Gullien, R. (2014) · Radiology · doi:10.1148/radiol.13131391 · Cited by 332
Domchek, S. M., Friebel, T. M., Neuhausen, S. L., Wagner, T., Evans, G., Isaacs, C., Garber, J. E., Daly, M. B., Eeles, R., Matloff, E., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70585-x · Cited by 327
Self-citationChetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6905 · Cited by 323
Piver, M. S., Jishi, M. F., Tsukada, Y., & Nava, G. (1993) · Cancer · doi:10.1002/1097-0142(19930501)71:9<2751::aid-cncr2820710911>3.0.co;2-j · Cited by 321
Levy‐Lahad, E., Catane, R., Eisenberg, S., Kaufman, B., Hornreich, G., Lishinsky, E., Shohat, M., Weber, B., Beller, U., Lahad, A., et al. (1997) · Europe PMC (PubMed Central) · Cited by 316
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
Moran, A., O’Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., Lalloo, F., & Evans, D. G. R. (2012) · Familial Cancer · doi:10.1007/s10689-011-9506-2 · Cited by 307
Self-citationTriple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
Shimelis, H., LaDuca, H., Hu, C., Hart, S. N., Na, J., Thomas, A., Akinhanmi, M., Moore, R. M., Brauch, H., Cox, A., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy106 · Cited by 305
Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., Dinan, M., McBroom, A. J., Hasselblad, V., Sanders, G. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9021 · Cited by 303
Germline BRCA1 mutations increase prostate cancer risk
Collaborators, T. U., Leongamornlert, D., Mahmud, N., Tymrakiewicz, M., Saunders, E., Dadaev, T., Castro, E., Goh, C., Govindasami, K., Guy, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.146 · Cited by 302
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., Bhatia, J., Stadler, Z., Fine, S. W., Reuter, V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2871 · Cited by 301
Self-citationBRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Goggins, M. G., Hruban, R. H., Cote, M. L., McWilliams, R. R., Roberts, N. J., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.153 · Cited by 295
Self-citationMagnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer
Stoutjesdijk, M. J., Boetes, C., Jager, G. J., Beex, L., Bult, P., Hendriks, J. H. C. L., Laheij, R. J. F., Massuger, L., van Die, L. E., Wobbes, T., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1095 · Cited by 289
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287
McAlpine, J. N., Hanley, G. E., Woo, M. M. M., Tone, A. A., Rozenberg, N., Swenerton, K. D., Gilks, C. B., Finlayson, S. J., Huntsman, D. G., & Miller, D. M. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.01.003 · Cited by 286
Re: Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer
Goffin, J., Chappuis, P. O., Wong, N., & Foulkes, W. D. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1754 · Cited by 284
Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype
Sawyer, S. L., Tian, L., Kähkönen, M., Schwartzentruber, J., Kircher, M., University of Washington Centre for Mendelian Genomics, FORGE Canada Consortium, Majewski, J., Dyment, D. A., Innes, A. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1156 · Cited by 283
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis
Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., Bernard, L., Maisonneuve, P., & Gandini, S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.018 · Cited by 281
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
Friedman, L. S., Gayther, S. A., Kurosaki, T., Gordon, D., Noble, B., Casey, G., Ponder, B. A. J., & Anton‐Culver, H. (1997) · PubMed · Cited by 275
Follow-up study of twenty-four families with Li-Fraumeni syndrome.
Garber, J. E., Goldstein, A. M., Kantor, A. F., Dreyfus, M., Fraumeni, J. F., & Li, F. P. (1991) · PubMed · Cited by 275
The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer
Couch, F. J., Johnson, M. R., Rabe, K. G., Brune, K., de Andrade, M., Goggins, M., Rothenmund, H., Gallinger, S., Klein, A., Petersen, G. M., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0783 · Cited by 275
Self-citationThe prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Young, Sr., Pilarski, R. T., Donenberg, T., Shapiro, C., Hammond, L. S., Miller, J., Brooks, K. A., Cohen, S., Tenenholz, B., DeSai, D., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-86 · Cited by 273
Risk-reducing mastectomy for the prevention of primary breast cancer
Carbine, N. E., Lostumbo, L., Wallace, J., & Ko, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub4 · Cited by 266
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis
Baretta, Z., Mocellin, S., Goldin, E., Olopade, O. I., & Huo, D. (2016) · Medicine · doi:10.1097/md.0000000000004975 · Cited by 260
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M., Kim‐Sing, C., Olsson, H., Ainsworth, P., Eisen, A., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21536 · Cited by 254
Self-citationThe Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer
Hartmann, L. C., & Lindor, N. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1503523 · Cited by 253
Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers
Lakhani, S. R., Manek, S., Penault-Llorca, F., Flanagan, A., Arnout, L., Merrett, S., McGuffog, L., Steele, D., Devilee, P., Klijn, J. G. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1029-3 · Cited by 252
Inherited p53 gene mutations in breast cancer.
Sidransky, D., Tokino, T., Helzlsouer, K. J., et al. (1992) · PubMed · Cited by 249
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
Nyberg, T., Frost, D., Barrowdale, D., Evans, D. G., Bancroft, E., Adlard, J., Ahmed, M., Barwell, J., Brady, A. F., Brewer, C., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.08.025 · Cited by 248
McLaughlin, J. R., Risch, H. A., Lubinski, J., Moller, P., Ghadirian, P., Lynch, H., Karlan, B., Fishman, D., Rosen, B., Neuhausen, S. L., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70983-4 · Cited by 247
Self-citationLi, X., You, R., Wang, X., Liu, C., Xu, Z., Zhou, J., Yu, B., Xu, T., Cai, H., & Zou, Q. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1465 · Cited by 234
Shu, C. A., Pike, M. C., Jotwani, A. R., Friebel, T. M., Soslow, R. A., Levine, D. A., Nathanson, K. L., Konner, J. A., Arnold, A. G., Bogomolniy, F., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1820 · Cited by 232
Self-citationLal, G., Liu, G., Schmocker, B., Kaurah, P., Özçelik, H., Narod, S. A., Redston, M. S., & Gallinger, S. (2000) · PubMed · Cited by 231
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230
Pijpe, A., Andrieu, N., Easton, D. F., Kesminiene, A., Cardis, E., Nogues, C., Gauthier-Villars, M., Lasset, C., Fricker, J.-P., Peock, S., et al. (2012) · BMJ · doi:10.1136/bmj.e5660 · Cited by 230
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer
Kast, K., Rhiem, K., Wappenschmidt, B., Hahnen, E., Hauke, J., Bluemcke, B., Zarghooni, V., Herold, N., Ditsch, N., Kiechle, M., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103672 · Cited by 230
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., Mandelker, D., Zehir, A., Capanu, M., Salo-Mullen, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy024 · Cited by 224
Self-citationGermline mutations in the TP53 gene.
Eeles, R. A. (1995) · PubMed · Cited by 211
Chlebowski, R. T., Rohan, T. E., Manson, J. E., Aragaki, A. K., Kaunitz, A., Stefanick, M. L., Simon, M. S., Johnson, K. C., Wactawski-Wende, J., O’Sullivan, M. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0494 · Cited by 211
Rosenthal, A. N., Fraser, L. S. M., Philpott, S., Manchanda, R., Burnell, M., Badman, P., Hadwin, R., Rizzuto, I., Benjamin, E., Singh, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9330 · Cited by 209
Heemskerk-Gerritsen, B. A. M., Seynaeve, C., van Asperen, C. J., Ausems, M. G. E. M., Collée, J. M., van Doorn, H. C., Gomez Garcia, E. B., Kets, C. M., van Leeuwen, F. E., Meijers-Heijboer, H. E. J., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv033 · Cited by 206
Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations
Levine, D. A., Argenta, P. A., Yee, C. J., Marshall, D. S., Olvera, N., Bogomolniy, F., Rahaman, J. A., Robson, M. E., Offit, K., Barakat, R. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.131 · Cited by 206
Self-citationBRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
Ferrone, C. R., Levine, D. A., Tang, L. H., Allen, P. J., Jarnagin, W., Brennan, M. F., Offit, K., & Robson, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5546 · Cited by 206
Self-citationZhong, Q., Peng, H.-L., Zhao, X., Zhang, L., & Hwang, W.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1816 · Cited by 203
Prediction of pathogenic mutations in patients with early-onset breast cancer by family history
Lalloo, F., Varley, J., Ellis, D., Moran, A., O'Dair, L., Pharoah, P., & Evans, D. G. R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12856-5 · Cited by 202
Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia
Offit, K., Levran, O., Mullaney, B., Mah, K., Nafa, K., Batish, S. D., Diotti, R., Schneider, H., Deffenbaugh, A., Scholl, T., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg072 · Cited by 201
Self-citationBirch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200
Identification of germline genetic mutations in patients with pancreatic cancer
Salo‐Mullen, E. E., O'Reilly, E. M., Kelsen, D. P., Ashraf, A. M., Lowery, M. A., Yu, K. H., Reidy, D. L., Epstein, A. S., Lincoln, A., Saldia, A., et al. (2015) · Cancer · doi:10.1002/cncr.29664 · Cited by 198
Self-citationTilanus‐Linthorst, M., Verhoog, L., Obdeijn, I., Bartels, K., Menke‐Pluymers, M., Eggermont, A., Klijn, J., Meijers‐Heijboer, H., van der Kwast, T., & Brekelmans, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10666 · Cited by 195
BRCA1 and BRCA2 mutations in a population-based study of male breast cancer
Basham, V. M., Lipscombe, J. M., Ward, J. M., Gayther, S. A., Ponder, B. A., Easton, D. F., & Pharoah, P. D. (2001) · Breast Cancer Research · doi:10.1186/bcr419 · Cited by 191
Biologic Characteristics of Interval and Screen-Detected Breast Cancers
Gilliland, F. D. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.743 · Cited by 187
Long-term results of screening with magnetic resonance imaging in women with BRCA mutations
Passaperuma, K., Warner, E., Causer, P. A., Hill, K. A., Messner, S., Wong, J. W., Jong, R. A., Wright, F. C., Yaffe, M. J., Ramsay, E. A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.204 · Cited by 183
GermlineTP53Mutations and the Changing Landscape of Li-Fraumeni Syndrome
Kamihara, J., Rana, H. Q., & Garber, J. E. (2014) · Human Mutation · doi:10.1002/humu.22559 · Cited by 182
Jakub, J. W., Peled, A. W., Gray, R. J., Greenup, R. A., Kiluk, J. V., Sacchini, V., McLaughlin, S. A., Tchou, J. C., Vierkant, R. A., Degnim, A. C., et al. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2017.3422 · Cited by 181
Ballinger, M. L., Best, A., Mai, P. L., Khincha, P. P., Loud, J. T., Peters, J. A., Achatz, M. I., Chojniak, R., Balieiro da Costa, A., Santiago, K. M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1968 · Cited by 180
Self-citationBRCA1 and BRCA2: from molecular genetics to clinical medicine.
Blackwood, M. A., & Weber, B. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1969 · Cited by 179
Gilbert, F. J., Tucker, L., Gillan, M. G. C., Willsher, P., Cooke, J., Duncan, K. A., Michell, M. J., Dobson, H. M., Lim, Y. Y., Suaris, T., et al. (2015) · Radiology · doi:10.1148/radiol.2015142566 · Cited by 178
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives
Lalloo, F., Varley, J., Moran, A., Ellis, D., O’Dair, L., Pharoah, P., Antoniou, A., Hartley, R., Shenton, A., Seal, S., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.032 · Cited by 175
Risk-Reducing Salpingo-Oophorectomy (RRSO) in BRCA Mutation Carriers
Powell, C. B., Chen, L.-M., McLennan, J., Crawford, B., Zaloudek, C., Rabban, J. T., Moore, D. H., & Ziegler, J. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821bc7e3 · Cited by 169
BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews
Kirchhoff, T., Kauff, N. D., Mitra, N., Nafa, K., Huang, H., Palmer, C., Gulati, T., Wadsworth, E., Donat, S., Robson, M. E., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0604 · Cited by 165
Self-citationSong, H., Cicek, M. S., Dicks, E., Harrington, P. A., Ramus, S. J., Cunningham, J. M., Fridley, B. L., Tyrer, J. P., Alsop, J., Jimenez‐Liñan, M., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu172 · Cited by 158
Findley, A. D., Siedhoff, M. T., Hobbs, K. A., Steege, J. F., Carey, E. T., McCall, C. A., & Steiner, A. Z. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.07.1997 · Cited by 155
Skates, S. J., Greene, M. H., Buys, S. S., Mai, P. L., Brown, P. H., Piedmonte, M., Rodriguez, G. C., Schorge, J. O., Sherman, M. E., Daly, M. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2750 · Cited by 154
Self-citationBiallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
Domchek, S. M., Tang, J.-B., Stopfer, J. E., Lilli, D. R., Hamel, N., Tischkowitz, M. D., Monteiro, Á. N. A., Messick, T. E., Powers, J., Yonker, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0421 · Cited by 153
Self-citationOvarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan, J. M., Boyd, J. A., Kauff, N. D., Robson, M. E., Scheuer, L., Narod, S. A., & Offit, K. (2002) · PubMed · Cited by 152
Self-citationSegregation analysis of cancer in families of childhood soft-tissue-sarcoma patients.
Lustbader, E. D., Williams, W. R., Bondy, M. L., Strom, S. S., & Strong, L. C. (1992) · PubMed · Cited by 148
Gastric cancer in individuals with Li-Fraumeni syndrome
Masciari, S., Dewanwala, A., Stoffel, E. M., Lauwers, G. Y., Zheng, H. W., Achatz, M. I., Riegert‐Johnson, D. L., Foretová, L., da Silva, E. M., DiGianni, L. M., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821628b6 · Cited by 148
Zuckerman, S. P., Conant, E. F., Keller, B. M., Maidment, A. D. A., Barufaldi, B., Weinstein, S. P., Synnestvedt, M. B., & McDonald, E. S. (2016) · Radiology · doi:10.1148/radiol.2016160366 · Cited by 148
Associations of High-Grade Prostate Cancer withBRCA1andBRCA2Founder Mutations
Agalliu, I., Gern, R. W., Leanza, S. M., & Burk, R. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1822 · Cited by 147
Effect of Oophorectomy on Survival After Breast Cancer inBRCA1andBRCA2Mutation Carriers
Metcalfe, K. A., Lynch, H. T., Foulkes, W. D., Tung, N., Kim‐Sing, C., Olopade, O. I., Eisen, A. F., Rosen, B. P., Snyder, C., Gershman, S., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0658 · Cited by 146
Screening MRI in Women With a Personal History of Breast Cancer
Lehman, C. D., Lee, J. M., DeMartini, W. B., Hippe, D. S., Rendi, M. H., Kalish, G., Porter, P. L., Gralow, J. R., & Partridge, S. C. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv349 · Cited by 145
Chaffee, K. G., Oberg, A. L., McWilliams, R. R., Majithia, N., Allen, B. A., Kidd, J., Singh, N., Hartman, A.-R., Wenstrup, R. J., & Petersen, G. M. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.85 · Cited by 144
Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy
Schrader, K. A., Hurlburt, J., Kalloger, S. E., Hansford, S., Young, S. S., Huntsman, D. D., Gilks, C. B., & McAlpine, J. N. (2012) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31825f3576 · Cited by 143
Early onset HER2‐positive breast cancer is associated with germline TP53 mutations
Melhem‐Bertrandt, A., Bojadzieva, J., Ready, K. J., Obeid, E. I., Liu, D. D., Gutierrez‐Barrera, A. M., Litton, J. K., Olopade, O. I., Hortobágyi, G. N., Strong, L. C., et al. (2011) · Cancer · doi:10.1002/cncr.26377 · Cited by 142
Self-citationThe risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study
Beiner, M. E., Finch, A., Rosen, B. P., Lubiński, J., Møller, P., Ghadirian, P., Lynch, H. T., Friedman, E., Sun, P., & Narod, S. A. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.08.004 · Cited by 139
Sherman, M. E., PIEDMONTE, M. R., Mai, P. L., Ioffe, O. B., Ronnett, B. M., Le, L. V., Ivanov, I., Bell, M. C., Blank, S. V., DiSilvestro, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1987 · Cited by 138
Prognosis of BRCA-associated breast cancer: a summary of evidence
Bordeleau, L., Panchal, S., & Goodwin, P. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0566-z · Cited by 135
Milne, R. L., Knight, J. A., John, E. M., Dite, G. S., Balbuena, R., Ziogas, A., Andrulis, I. L., West, D. W., Li, F. P., Southey, M. C., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0376 · Cited by 135
van den Broek, A. J., Schmidt, M. K., Veer, L. V. ‘., Tollenaar, R. A. �. �., & van Leeuwen, F. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120189 · Cited by 134
Lowry, K. P., Lee, J. M., Kong, C. Y., McMahon, P. M., Gilmore, M. E., Chubiz, J. E. C., Pisano, E. D., Gatsonis, C. A., Ryan, P. D., Ozanne, E. M., et al. (2011) · Cancer · doi:10.1002/cncr.26424 · Cited by 134
Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States
Ding, Y. C., Steele, L., Kuan, C.-J., Greilac, S., & Neuhausen, S. L. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1195-2 · Cited by 130
Lee, E., McKean‐Cowdin, R., Ma, H., SPICER, D. V., Berg, D. V. D., Bernstein, L., & Ursin, G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.6446 · Cited by 130
Gordhandas, S., Norquist, B. M., Pennington, K. P., Yung, R. L., Laya, M. B., & Swisher, E. M. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.12.014 · Cited by 128
Self-citationHu, C., Polley, E. C., Yadav, S., Lilyquist, J., Shimelis, H., Na, J., Hart, S. N., Goldgar, D. E., Shah, S. H., Pesaran, T. F., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa023 · Cited by 124
BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50
Haile, R. W., Thomas, D. C., McGuire, V. M., Felberg, A., John, E. M., Milne, R. L., Hopper, J. L., Jenkins, M. A., Levine, A. J., Daly, M. M., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0258 · Cited by 123
Self-citationGillanders, W. E., & Simon, P. O. (2005) · The Women s Oncology Review · doi:10.1080/14733400500235731 · Cited by 123
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations: Table 1
Wilson, J. R. F., Bateman, A. C., Hanson, H., An, Q., Evans, G., Rahman, N., Jones, J. L., & Eccles, D. M. (2010) · Journal of Medical Genetics · doi:10.1136/jmg.2010.078113 · Cited by 122
Phi, X.-A., Saadatmand, S., de Bock, G. H., Warner, E., Sardanelli, F., Leach, M. O., Riedl, C. C., Trop, I., Hooning, M. J., Mandel, R., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.32 · Cited by 122
Narod, S. A., Lubiński, J., Ghadirian, P., Lynch, H. T., Møller, P., Foulkes, W. D., Rosen, B. P., Kim‐Sing, C., Isaacs, C. J., Domcheck, S., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70624-6 · Cited by 112
Chompret, A. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01361-x · Cited by 110
Fostira, F., Tsitlaidou, M., PAPADIMITRIOU, C. A., Pertesi, M., Timotheadou, E. T., Stavropoulou, A. V., Glentis, S., Bournakis, E., Bobos, M., Pectasides, D. G., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2021-9 · Cited by 110
Giri, V. N., Hegarty, S., Hyatt, C., O’Leary, E., Garcia, J., Knudsen, K. E., Kelly, W. K., & Gomella, L. G. (2018) · The Prostate · doi:10.1002/pros.23739 · Cited by 109
Le‐Petross, H. T., Whitman, G. J., Atchley, D. P., Yuan, Y., Gutierrez‐Barrera, A. M., Hortobágyi, G. N., Litton, J. K., & Arun, B. (2011) · Cancer · doi:10.1002/cncr.25971 · Cited by 105
Self-citationvan den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104
Cited by
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian
Mersch, J., Jackson, M. A., Park, M., Nebgen, D., Peterson, S. K., Singletary, C., Arun, B. K., & Litton, J. K. (2015) · Cancer · doi:10.1002/cncr.29041 · Cited by 511
Self-citationHereditary diffuse gastric cancer: updated clinical practice guidelines
Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., van Dieren, J. M., Harris, K. L., Hoogerbrugge, N., Oliveira, C., van der Post, R. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30219-9 · Cited by 491
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., McGuire, V., Ladabaum, U., Kobayashi, Y., Lincoln, S. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6607 · Cited by 485
Self-citationSessa, C., Balmaña, J., Bober, S. L., Cardoso, M. J., Colombo, N., Curigliano, G., Domchek, S. M., Evans, D. G., Fischerova, D., Harbeck, N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.004 · Cited by 295
Self-citation
Metadata
- Authors
- Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., CGC, Karlan, B. Y., Khan, S., Klein, C., Kohlmann, W., CGC, Kurian, A. W., Laronga, C., Litton, J. K., Mak, J. S., LCGC, Menendez, C. S., Merajver, S. D., Norquist, B. S., Offit, K., Pederson, H. J., Reiser, G., CGC, Senter-Jamieson, L., CGC, Shannon, K. M., Shatsky, R., Visvanathan, K., Weitzel, J. N., Wick, M. J., Wisinski, K. B., Yurgelun, M. B., Darlow, S. D., & Dwyer, M. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2021-01-06
- Volume
- 19
- Issue
- 1
- Pages
- 77-102
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3118983547
- Cited by
- 1,112
- References
- 249
- FWCI
- 106.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.